scholarly journals 2013 Trends in anogenital warts incidence: Potential impact of human papillomavirus vaccination, TennCare 2006–2015

2018 ◽  
Vol 2 (S1) ◽  
pp. 89-89
Author(s):  
Jaimie Z. Shing ◽  
Marie Griffin ◽  
Manideepthi Pemmaraju ◽  
Edward Mitchel ◽  
Pamela Hull

OBJECTIVES/SPECIFIC AIMS: We aimed to assess trends in incidence of genital warts across human papillomavirus (HPV) vaccine-eligible and nonvaccine-eligible age groups to determine the impact of the HPV vaccine among Medicaid enrollees in the state of Tennessee. METHODS/STUDY POPULATION: We analyzed 2006–2014 medical and pharmaceutical claims data from TennCare (Tennessee’s Medicaid program) enrollees aged 15–64 years. Incident cases of genital warts were defined as persons 12 months disease free and: (1) a diagnosis of condyloma acuminatum, or (2) a diagnosis of viral warts and genital-specific procedure, or (3) a prescription for genital warts medication and genital-specific procedure. Mann-Kendall trend tests were performed to assess for significant trends in incidence of genital warts by sex and age group; average annual percent changes were calculated to quantify these trends. RESULTS/ANTICIPATED RESULTS: Our analysis is in progress. We hypothesize that we will observe declines in genital warts among younger, vaccine-eligible age groups and no changes in older, nonvaccine-eligible age groups, with largest declines among females aged 15–19 years from 2006 to 2014. We also expect to see declines among younger males due to herd protection, with greater declines after 2011, when the vaccine was approved for males. DISCUSSION/SIGNIFICANCE OF IMPACT: Significant declines among younger compared with older age groups would suggest HPV vaccine effectiveness for preventing genital warts.

Author(s):  
Louise Baandrup ◽  
Christian Dehlendorff ◽  
Susanne K Kjaer

Abstract Background Increasing evidence suggests that 1-dose human papillomavirus (HPV) vaccination may protect significantly against HPV-related disease. We provide nationwide, real-world data on the risk of genital warts (GWs) after <3 vaccine doses. Methods All Danish women born in 1985–2003 were identified, and individual-level vaccination data were retrieved. The cohort was followed up for first occurrence of GWs until 31 December 2016. Using Poisson regression, we calculated incidence rates (IRs) of GWs per 100 000 person-years and IR ratios (IRRs) with corresponding 95% confidence intervals (CIs) for GWs, according to vaccination status, age at first dose, and calendar time. Results The cohort comprised 1 076 945 girls and women, of whom 485 408 were vaccinated. For girls initiating vaccination at age 12–14 years and 15–16 years, 1-dose vaccine effectiveness (VE) was 71% (IRR = 0.29; 95% CI, .22–.38) and 62% (0.38; .29–.49), respectively, compared with unvaccinated girls. In the same age groups, 2-dose VE was 78% (IRR, 0.22; 95% CI, .18–.26) and 68% (0.32; .26–.38), respectively. After 2009, the IRRs for 3 versus 1 dose and 2 versus 1 dose increased towards unity over calendar time, being 0.69 (95% CI, .57–.84) and 0.86 (.68–1.08) in 2016, respectively. Conclusions In this study, 1 or 2 doses of quadrivalent HPV vaccine was associated with substantial protection against GWs in girls vaccinated at age ≤16 years. The 1-dose VE approached that of 3 or 2 doses over calendar time, probably reflecting the impact of herd protection.


Sexual Health ◽  
2016 ◽  
Vol 13 (5) ◽  
pp. 489 ◽  
Author(s):  
Eric P. F. Chow ◽  
Christopher K. Fairley

Australian-born women aged ≤32 years were eligible for the free female human papillomavirus (HPV) vaccination program introduced in 2007. A total of 1165 heterosexual couples attending the Melbourne Sexual Health Centre between 2011 and 2014 were included in this analysis. Findings showed the odds of having penile warts was 0.52-fold lower among men who had a female partner aged ≤32 years compared with men who had a female partners aged >32 years. This suggests men would have received herd protection from their female partners and hence they are at lower risk of acquiring genital warts.


2018 ◽  
Vol 57 (13) ◽  
pp. 1523-1531 ◽  
Author(s):  
Nora B. Henrikson ◽  
Weiwei Zhu ◽  
Lauren Baba ◽  
Matthew Nguyen ◽  
Heidi Berthoud ◽  
...  

This study evaluated the impact of health system–based outreach and reminders on human papillomavirus (HPV) vaccine series initiation and completion. Parents of 10 to 12 year olds (n = 1805) were randomized to receive either (1) an outreach letter and brochure recommending HPV vaccination followed by automated HPV vaccine reminders or (2) usual care. We interviewed a subset of 50 parents to assess program acceptability. Outcomes were HPV vaccine initiation during the study period and on-time series completion. Rates of HPV vaccine initiation during the study period (July 2015 to August 2016) were similar between the intervention and control groups, but initiation within 120 days of randomization was higher in the intervention group (23.6% and 18.8%, P = .04) as was completion during the study period (10.3% vs 6.8%, P = .04). Reminders for doses 2 and 3 did not affect completion. The program was acceptable to parents. This study provides evidence that health system–based outreach and reminders can improve HPV vaccination.


2014 ◽  
Vol 6 (3) ◽  
Author(s):  
Andrew Wilson ◽  
Ryan J Welch ◽  
Mia Hashibe ◽  
Jessica Greenwood ◽  
Brian Jackson ◽  
...  

Nationwide positivity rates of high-risk human papillomavirus for the United States before and since the introduction of a Human Papillomavirus (HPV) vaccine in 2006 would provide insight into the population impact of HPV vaccination.  Data for high-risk HPV testing results from January 1, 2004 to June 1, 2013 at a national reference laboratory were retrospectively analyzed to produce 757,761 patient records of women between the ages of 14 and 59. Generalized linear models and finite mixture models were utilized to eliminate sources of bias and establish a population undergoing standard gynecological screening. Unadjusted positivity rates for high-risk HPV were 27.2% for all age groups combined.  Highest rates occurred in women aged 14 to 19.  While the positivity rates decreased for all age groups from 2004 to 2013, the higher age categories showed less downward trend following vaccine introduction, and the two age categories 20 to 24 and 25 to 29 showed a significantly different downward trend between pre- and post-vaccine time periods (-0.1% per year to -1.5% per year, and 0.4 % per year to -1.5% per year, respectively).  All other age groups had rates of change that became less negative, indicating a slower rate of decline.In evaluating the surveillance tool, we find that it is important to consider many sources of heterogeneity, e.g., age, type of test, location, and type of testing center, and also consider quantitative methods of adjustment and distribution assessment to construct a useful surveillance tool.  Further studies should expand on this methodology.The results of the surveillance tool indicate a downward trend in vaccine-appropriate age groups consistent with uptake of the HPV vaccine. The pre-post rate changes were in direct contrast between the age-appropriate groups and the groups too old for the HPV vaccine, further indicating the surveillance tool may be detecting the impact of the HPV vaccine over time. After refinement, this surveillance tool should remain in place to observe the future impact of the HPV vaccine. 


2020 ◽  
Vol 41 (1) ◽  
pp. 89-99
Author(s):  
Chigozie Anastacia Nkwonta ◽  
DeAnne K. Hilfinger Messias ◽  
Tisha Felder ◽  
Kathryn Luchok

We explored the impact of two community-based educational interventions on Nigerian adults’ knowledge and intention to take or encourage human papillomavirus (HPV) vaccine and cervical screenings. Face-to-face presentation and printed pamphlet intervention were delivered to 266 men and women aged 18 to 65 years in 12 locations in urban setting. At baseline, the majority (80%) had poor knowledge of HPV, and less than 12% had ever received or have a family member who had received HPV vaccine or cervical screening. Postintervention, there was significant increase (>70%) in the participants knowledge and intention to take or encourage HPV vaccination and cervical screening. In addition, more than half were willing to pay for HPV vaccine and screening even when expensive. Gender-focused and context-specific low-cost community-based educational interventions are effective in increasing HPV vaccine and cervical screening in sub-Saharan Africa.


2019 ◽  
Vol 6 (4) ◽  
pp. 317-326
Author(s):  
Gui-Dan Tang ◽  
Gu-Qing Zeng ◽  
Bi-Xia Zhao ◽  
Yun-Li Li ◽  
Rong Wang ◽  
...  

Abstract Objectives To systematically review the knowledge attitudes and the influential factors on human papillomavirus (HPV) vaccination among Chinese women. Methods Published studies on knowledge and attitudes of HPV vaccination for preventing cervical cancer among Chinese female population were retrieved using the major Chinese and English databases. Meanwhile, handwork retrieval was also conducted and the references including in the literature were retrieved. The quality of the literature was rigorously evaluated and extracted independently by two researchers and the data were analyzed and described by review manager 5.3 (RevMan5.3) software. Results In all, 19 articles including 8 articles in Chinese and 11 in English were chosen. A total of 30,176 participants were included and the sample size ranged from 64 to 6,024. The overall awareness of HPV and HPV vaccine among Chinese women was at a low level. Chinese women generally showed poor knowledge about HPV and HPV vaccine. Acceptance of HPV vaccination among Chinese women was at a high level. Vaccination intentions were influenced by the theory of planned behavior (TPB) and measured by attitudes subjective norms and perceived behavioral control. Conclusions The health authorities may evaluate and develop TPB-based interventions to increase HPV vaccination intentions of Chinese women. HPV vaccination programs should focus on carrying out multi-level and targeted health education and developing effective public health strategies after balancing the cost and benefit of HPV vaccine program. Medical staff should play the positive role in promoting the use of HPV vaccines in China. Integration of policy and community perspectives and multi-level interventions are essential to maximize the public health benefits of HPV vaccination.


2016 ◽  
Vol 2 (3_suppl) ◽  
pp. 72s-73s
Author(s):  
Sean Parkinson ◽  
Ian Bambury ◽  
Carole Rattray

Abstract 51 Background: Cervical cancer is the second most common cancer in Jamaica with an incidence of 17.4/100,000. (1). Cervical cancer is acquired sexually, with the human papilloma virus (HPV) being the most important causative agent (2,3). HPV infection is associated with the development of other cancers such as anogenital, vaginal, vulvar and anal cancers in women, and penile and anal cancers in men.(2) It is also responsible for genital warts and oropharyngeal cancer in both men and women. Two vaccines were approved for the prevention of cervical cancer by the Food and Drug Administration (FDA) and are available in Jamaica (4,5). This study assessed the knowledge and attitudes in a male cohort towards HPV and HPV vaccine. Methods: This was a cross-sectional study in which two hundred male students were recruited. Information for this study was gathered from responses given in a self-administered questionnaire. Data was analyzed using the statistical package for social sciences (SPSS) version 20. Results: The mean age of the respondents was 22.6 years. 50.5% stated that they had heard of HPV. Of those who knew of the HPV, only 37.6% vs 39.6% of respondents reported that sexual intercourse was a requirement for HPV transmission, while 22.8% did not know. 43% reported knowing that HPV causes genital warts and 42% knew of an association with cervical cancer. 16.5% of the respondents knew of the HPV vaccine. Only 21.2% knew that the HPV vaccine protects against cervical cancer while the remaining 78.8% either said that it didn't provide protection or did not know. 15.3% knew that the vaccine is approved for both males and females while 84.7% did not know. Conclusion: There was significant knowledge deficit in the awareness of HPV and the HPV vaccine in our male university students. Gibson, T.N., et al., Age-specific incidence of cancer in Kingston and St. Andrew, Jamaica, 2003-2007. West Indian Med J, 2010. 59(5): p. 456-64. Centers for Disease Control and Prevention. Basic information about HPV –associated cancers. Available at: http://www.cdc.gov/cancer/hpv/basic_info . 2013. Bosch, F.X. and S. de Sanjose, Chapter 1: Human papillomavirus and cervical cancer-- burden and assessment of causality. J Natl Cancer Inst Monogr, 2003(31): p. 3-13. FDA licensure of bivalent Human Papillomavirus vaccine (HPV2,Cervarix) for use in females and updated vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP) .Centers For Disease Control and Prevention (CDC). MMWR Morb Mort Wkly Rep, 2010(59): p. 626-9. FDA, “FDA Approves New Vaccine Indication for Gardasil to Prevent Genital Warts in Men and Boys,” Bethesda, Md, USA. 2009. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST: No COIs from the authors.


Sign in / Sign up

Export Citation Format

Share Document